<2>Moderna Rises as Up to $2.25 Billion Settlement for COVID Vaccine Patent Dispute to Remove Overhang
<3>The COVID-19 pandemic has been a catalyst for innovation in the pharmaceutical industry, with numerous companies working tirelessly to develop effective vaccines. One such company, Moderna Therapeutics, has been at the forefront of this effort, and its COVID-19 vaccine has been widely adopted around the world. However, the company has faced significant challenges in recent years, including patent disputes that have weighed heavily on its stock price.
<3>The patent dispute in question revolves around Moderna’s COVID-19 vaccine, which has been a major success for the company. The vaccine has been widely adopted around the world, and it has been instrumental in helping to bring the pandemic under control. However, the company has faced challenges in recent years, including patent disputes with other companies that have sought to develop similar vaccines.
<4 href='https://bloomberg.com' target